BRIDGEWATER, N.J. — Amneal Pharmaceuticals has bought rights to four generic drugs from Actavis, Amneal said Monday.
The generic drug maker announced the purchase of four drugs, two of which are currently marketed, one of which is awaiting Food and Drug Administration approval, and another of which is approved, but not marketed. The respective drugs are the contraceptive Zenchent Fe (norethindrone acetate; ethinyl estradion), a generic version of Femcon Fe; another generic norethindrone acetate and ethinyl estradiol product that is a generic version of Lo Loestrin Fe; the osteoporosis drug risendronate sodium, a generic version of Atelvia; and a third norethindrone acetate and ethinyl estradiol product that is a generic version of Loestrin 24 Fe.
Amneal's acquisition of the drugs is dependent on the closing of Actavis' purchase of Warner Chilcott. Financial terms of the Amneal-Actavis deal were not disclosed.